Quick Listen: Scrip’s Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: new US warnings for JAK inhibitors; strong new heart failure results for Jardiance; good head-to-head results for Pfizer in atopic dermatitis; US payers and drug exclusion lists; and a look ahead at key expected hematology launches.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 3 September 2021, including: US warnings for JAK inhibitors; strong new heart failure results for Jardiance; good head-to-head results for Pfizer Inc. in atopic dermatitis; US payers and drug exclusion lists; and a look ahead at key expected hematology launches.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "BI/Lilly's Jardiance Crowned As Heart Failure Game Changer After EMPEROR-Preserved" - Scrip, 29 Aug, 2021.)
(Also see "Pfizer's Oral Abroctinib Bests Injectable Dupixent In Atopic Dermatitis Trial" - Scrip, 30 Aug, 2021.)
(Also see "The Booming Business Of Drug Exclusions" - Scrip, 27 Aug, 2021.)
(Also see "Five Hematology Drug Launches To Look Out For In 2022" - Scrip, 30 Aug, 2021.)